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A pragmatic cluster randomized controlled trial of early intervention for chronic
obstructive pulmonary disease by practice nurse-general practitioner teams:
Study Protocol
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of disability,
hospitalization, and premature mortality. General practice is well placed to diagnose and manage COPD,
but there is a significant gap between evidence and current practice, with a low level of awareness and
implementation of clinical practice guidelines. Under-diagnosis of COPD is a world-wide problem, limiting
the benefit that could potentially be achieved through early intervention strategies such as smoking
cessation, dietary advice, and exercise. General practice is moving towards more structured chronic
disease management, and the increasing involvement of practice nurses in delivering chronic
care.Design: A pragmatic cluster randomised trial will test the hypothesis that intervention by a practice
nurse-general practitioner (GP) team leads to improved health-related quality of life and greater
adherence with clinical practice guidelines for patients with newly-diagnosed COPD, compared with usual
care. Forty general practices in greater metropolitan Sydney Australia will be recruited to identify patients
at risk of COPD and invite them to attend a case finding appointment. Practices will be randomised to
deliver either practice nurse-GP partnership care, or usual care, to patients newly-diagnosed with
COPD.The active intervention will involve the practice nurse and GP working in partnership with the
patient in developing and implementing a care plan involving (as appropriate), smoking cessation,
immunisation, pulmonary rehabilitation, medication review, assessment and correction of inhaler
technique, nutritional advice, management of psycho-social issues, patient education, and management
of co-morbidities.The primary outcome measure is health-related quality of life, assessed with the St
George's Respiratory Questionnaire 12 months after diagnosis. Secondary outcome measures include
validated disease-specific and general health related quality of life measures, smoking and immunisation
status, medications, inhaler technique, and lung function. Outcomes will be assessed by project officers
blinded to patients' randomization groups.Discussion: This study will use proven case-finding methods to
identify patients with undiagnosed COPD in general practice, where improved care has the potential for
substantial benefit in health and healthcare utilization. The study provides the capacity to trial a new
model of team-based assessment and management of newly diagnosed COPD in Australian primary
care.Trial registration: ACTRN12610000592044\. 2012 Bunker et al.; licensee BioMed Central Ltd.
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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of disability, hospitalization, and
premature mortality. General practice is well placed to diagnose and manage COPD, but there is a significant gap
between evidence and current practice, with a low level of awareness and implementation of clinical practice
guidelines. Under-diagnosis of COPD is a world-wide problem, limiting the benefit that could potentially be
achieved through early intervention strategies such as smoking cessation, dietary advice, and exercise. General
practice is moving towards more structured chronic disease management, and the increasing involvement of
practice nurses in delivering chronic care.
Design: A pragmatic cluster randomised trial will test the hypothesis that intervention by a practice nurse-general
practitioner (GP) team leads to improved health-related quality of life and greater adherence with clinical practice
guidelines for patients with newly-diagnosed COPD, compared with usual care. Forty general practices in greater
metropolitan Sydney Australia will be recruited to identify patients at risk of COPD and invite them to attend a case
finding appointment. Practices will be randomised to deliver either practice nurse-GP partnership care, or usual
care, to patients newly-diagnosed with COPD.
The active intervention will involve the practice nurse and GP working in partnership with the patient in
developing and implementing a care plan involving (as appropriate), smoking cessation, immunisation, pulmonary
rehabilitation, medication review, assessment and correction of inhaler technique, nutritional advice, management
of psycho-social issues, patient education, and management of co-morbidities.
The primary outcome measure is health-related quality of life, assessed with the St George’s Respiratory
Questionnaire 12 months after diagnosis. Secondary outcome measures include validated disease-specific and
general health related quality of life measures, smoking and immunisation status, medications, inhaler technique,
and lung function. Outcomes will be assessed by project officers blinded to patients’ randomization groups.
Discussion: This study will use proven case-finding methods to identify patients with undiagnosed COPD in
general practice, where improved care has the potential for substantial benefit in health and healthcare utilization.
The study provides the capacity to trial a new model of team-based assessment and management of newly
diagnosed COPD in Australian primary care.
Trial registration: ACTRN12610000592044\
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Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality [1], ranked globally in 2002 as the fifth leading cause of death [2] and
the seventh leading cause of disease burden after ischaemic heart disease and stroke. In Australia, COPD is the
fourth leading cause of death for males (4.2% of all
deaths) and the sixth leading cause of death for women
(3.3% of all deaths); it is also a contributory cause of
death in many patients with coronary heart disease or
cancer [3]. In the Burden Of Obstructive Lung Disease
survey (BOLD), the prevalence of airflow limitation
(GOLD Stage II or higher) in Australians aged ≥40 years
was 10.8% [4], whereas the prevalence of doctordiagnosed COPD in the same population was 5.9% [5].
Clinically, COPD is characterised by airflow limitation
that is not fully reversible, and is associated with an
enhanced chronic inflammatory response to noxious
particles or gases [6]. Patients typically present with
breathlessness, cough, and sputum production. The
most important cause in developed countries is cigarette
smoking, and up to 50% of smokers may eventually develop clinically significant COPD [7].
Even mild to moderate COPD is associated with
impaired health status [8]. Patients with COPD have
increased healthcare utilisation before diagnosis, raising
the possibility that earlier diagnosis may allow more rational and directed use of healthcare resources [9]. The
feasibility of a COPD case-finding approach has been
established. For example, in an Australian study in 2007,
20% of patients identified as being at risk of COPD
responded to invitations to be screened and of these
20% had a new diagnosis of COPD on spirometric criteria [10]. This is similar to findings from primary care
studies in other countries [11-13]. For diagnosis of
COPD, spirometry is required [6], and standards have
been developed for the performance of spirometry in
primary care [14]. Practice nurses can feasibly and successfully undertake spirometry [13,15]; as for other
health professionals, approximately six hours of training
are required [16].
Clinical practice guidelines have been developed and
disseminated for the diagnosis and management of
COPD [6], including in Australia (COPD-X guidelines)
[17]. Despite the high level evidence for the efficacy of
guidelines-based interventions, the care provided for
patients with COPD in community settings indicates low
levels of awareness and implementation of these guidelines [18]. Medication use is often not in accordance
with guidelines [19,20], and a high proportion of patients
prescribed inhalers use them incorrectly [21,22].
Effective treatment for COPD improves symptoms,
prognosis, and quality of life. Smoking cessation is the
most effective measure to reduce progression of the
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disease [23]. Because smoking cessation may become
less effective at altering the course of disease in patients
with severe COPD, interventions that target patients
with mild and moderate disease may be more effective
[24]. In the Lung Health Study [25] smokers with early
COPD who were assigned to a smoking cessation intervention had fewer respiratory symptoms after five years
follow-up than those who were not. Smokers diagnosed
with COPD [26] or who are told their ‘lung age’ [27]
may be more likely to cease smoking.
General practice is well placed to diagnose COPD and
provide early intervention and longer-term management
[28,29]. Care planning and a team approach are effective
in the management of chronic disease. Care planning by
general practitioners (GPs) has been shown to improve
the clinical outcomes for other chronic diseases such as
diabetes [30] and asthma [31], but GPs need more support to develop and implement multidisciplinary care
plans [32,33] Current guidelines recommend the use of
multidisciplinary care plans in the management of
patients with COPD [17].
Practice nurses are increasingly contributing to chronic
disease management. Specialised nurses have contributed
to the care of patients with diabetes and COPD, and there
is evidence of improvements in patient self-care, quality of
life, and satisfaction [34]. A Cochrane review [35] of nursing outreach programs for COPD found significant gains
in health-related quality of life for patients with moderate
COPD, but the review highlighted the lack of high quality
studies and concluded that further study was required.
While the role of specialist nurses in contributing to the
care of patients with COPD has been examined [35-37]
and some evidence of benefit in disease-specific quality of
life has been found, there are few studies examining
the potential role of practice nurses working in partnership with GPs in providing more coordinated,
integrated, and evidence-based care for patients with newlydiagnosed COPD.
Study aims

The primary aim is to assess the effectiveness of early
intervention by a GP-nurse team applying evidencebased guidelines, compared with usual care, in the
assessment and management of patients newly diagnosed with COPD. Secondary aims are to assess the acceptability of the two management approaches to GPs,
nurses and patients, and to assess the utility of the
COPD Diagnostic Questionnaire (CDQ) and COPD
Assessment Test (CAT) in an Australian population.
Study hypothesis

The study hypothesizes that intervention by a GPpractice nurse team leads to improved health-related
quality of life and greater adherence with clinical
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practice guidelines for patients with newly-diagnosed
COPD, compared with usual care.

Methods
Study approvals

The PELICAN study (Primary care EarLy Intervention
for Copd mANagement) is a pragmatic cluster randomized controlled study with two treatment arms, which
is being conducted in greater metropolitan Sydney, Australia. The study is funded by the National Health and
Medical Research Council of Australia (Project Grant
No. 630421). Ethical approval has been obtained from
the Human Research Ethics Committee, University of
New South Wales (HREC 10015). The project has been
registered with the Australian Clinical Trials Registry
(ACTRN12610000592044).

Study design

This pragmatic cluster randomized controlled trial will
test the hypothesis that early intervention by a practice
nurse-GP partnership will improve outcomes for
patients newly diagnosed with COPD, compared with
usual care. Because the intervention involves a team approach by treating practitioners, randomization will
occur at the practice level rather than at the level of individual patients (CONSORT guidelines for cluster trials
[38,39]). All participating practices will use case-finding
methods to identify a cohort of patients with newly diagnosed COPD.
The research plan, identifying recruitment strategies,
randomization, data collection points, and the relationships between intervention and control groups in
the two arms are summarised in Figure 1. Because it
is a complex intervention with potential for variable

STUDY
PROCESSES

DATA COLLECTION
FROM PATIENTS
by research team

Practice recruitment

PN spirometry and casefinding workshop

Randomisation of
practices

Identification of eligible
patients at risk of COPD

Usual care practices sent
copy of COPD guidelines

Intervention training
workshops for PN and GP

Case-finding visits

Case-finding visits

Usual care for patients
with newly-diagnosed
COPD

GP-PN team management
of patients with newlydiagnosed COPD

Visit 1 (<1 month
after diagnosis)

Visit 2 (6 months)

Visit 3 (12 months)
Figure 1 Study and data collection processes.
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implementation, there will be a focus on process evaluation as well as quantitative outcome measures.

Inclusion criteria
GPs and practice nurses

Practices will be eligible to participate if they have
computer-based patient records, employ at least one
practice nurse, and have a spirometer. More than one
GP per practice may be involved in the study. Written
informed consent will be obtained from GP(s) and practice nurse(s).

Page 4 of 10

Recruitment
GP and practice nurse recruitment

Recruitment will be conducted with assistance from
Divisions of General Practice (local organisations of
GPs) in the greater Sydney area. GPs and practice nurses
will be provided with an information sheet and asked to
provide written consent. All practices expressing an
interest in taking part in the project will be visited by an
investigator (SD) to discuss the study, answer questions,
and obtain consent from the GP and practice nurse. Further recruitment strategies will include provision of
study information packs at GP and practice nurse workshops and conferences, and by email to members of the
Australian Practice Nurses Association.

Patients

Patients will be eligible for inclusion if they have
attended the practice at least twice, with at least one
visit in the preceding 12 months, and have risk factors
for COPD (aged 40 to 85, and with a documented history of smoking). Patients will be excluded if they have a
recorded diagnosis of COPD, are unable to understand
English sufficiently to complete study questionnaires or
procedures, or have cognitive impairment.

Randomization and allocation concealment

Practices will be randomized to deliver either a practice
nurse-GP team management approach, or usual care, to
patients with newly-diagnosed COPD. Randomization will
be undertaken after the nurses have completed spirometry
and case-finding training, and before case-management
training for the intervention group. Randomization will be
carried out independently of study and practice staff by a
statistician separate to the study team using a computergenerated randomization program, with a minimisation algorithm to ensure a balance of practice characteristics that
could potentially affect study outcomes. These characteristics are: practice size, as indicated by the number of practice nurses (1 or >1); socio-economic status, classified
according to Socio-Economic Indexes for Areas (SEIFA,
[40]) (low: SEIFA 1-5, high: SEIFA 6-10); and participation
by the GP in significant (>6 hours) COPD education activities within the last six months (yes or no). Allocation concealment will be ensured as group allocation will be
conducted at the same time as randomization. Practices
will be informed about their group allocation by fax.

Blinding

Participating GPs, practice nurses and patients will not
be blinded to the true aims of the study, nor to their
randomization group. Project officers, who will collect
study outcome measures, will be blinded to group allocation as will the statistician undertaking the analyses.

Intervention and Control Groups: Patient recruitment

For both randomization groups, patient recruitment will
involve three stages:
1. Potentially eligible patients, i.e., those at risk of
COPD (aged 40 to 85, with documented smoking
history) will be identified through a search of the
practice electronic records by research assistants
and practice staff who have no involvement in
patient care.
2. Eligible patients will be recruited by a letter from the
practice inviting them to a case-finding visit and
management of COPD, if diagnosed. The letter will
include a brief description of the research and an
invitation to participate, and a response form and
reply-paid envelope. Non-responders will be followed
up by GP practice staff by telephone.
3. Patients who contact the practice in response to the
letter will be given an appointment for the
case-finding visit with the practice nurse. The
consent form will be signed at the start of the
case-finding visit.
For eligible patients who decline to participate in a
case-finding visit, basic de-identified information (age,
gender, language spoken) will be collected from the
practice to allow examination of response bias.
Training of GPs and practice nurses
Intervention and Control Groups—case-finding training of
practice nurses for diagnosis of COPD

All practice nurses, before randomization, will receive
training in case-finding for diagnosis of COPD. For practice nurses, this comprises a full-day workshop covering
the case-finding approach to diagnosis of COPD, and an
evening follow-up workshop approximately two weeks
later. Because spirometry is essential to the accurate
diagnosis and assessment of COPD [6], detailed training
in the performance and interpretation of spirometry will
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be provided (total, eight hours), based on the American
Thoracic Society and the European Respiratory Society
(ATS/ERS) lung function guidelines of 2005 [41,42].
Nurses will receive practical training on their practice’s
own spirometer, and calibration of each spirometer will
be checked during the workshop. The follow-up workshop will include revision of spirometry and the processes for the case-finding appointment.

the Australian COPD guidelines [17]. At the end of the
study, after conclusion of all data collection for all practices, GPs and practice nurses in the control group will
be offered a workshop on assisting patients to optimise
their inhaler technique.

Intervention Group only—training in GP-nurse team
management of newly-diagnosed COPD

At the case-finding visit, the practice nurse will first obtain written informed consent for the case-finding
process and for participation in the study if COPD is
diagnosed; patients will also be asked to consent to release of their contact details to the project officer for arranging data collection visits. The practice nurse will
administer a questionnaire including demographic data
and the COPD Diagnosis Questionnaire (CDQ, [48]),
without calculation of the CDQ score, and will perform
spirometry before and after two inhalations of salbutamol. Practice nurses will be provided with a computerbased toolkit [49] to assist in diagnosis of COPD, which
will be based on post-bronchodilator FEV1/FVC <0.7
[6,17]. The patient consent and demographic/contact
details, spirometry printout, diagnosis, and CDQ responses will be faxed to the project officer. Quality of all
spirometry traces will be reviewed by one investigator
(AC), and if necessary, feedback or additional training in
spirometry will be provided to the practice nurse, initially by telephone, with face-to-face support, if needed.
Patients will be included in the study on the basis of the
COPD diagnosis assigned by the nurse and/or GP from
the case-finding spirometry.
All current smokers—irrespective of the results of spirometry or practice randomisation—will be offered smoking
cessation advice and resources at the case-finding visit.
Patients with newly diagnosed COPD will be offered management and follow-up, as below, according to whether the
practice is in the intervention or control group. If spirometry appears abnormal for other reasons (bronchodilator
reversibility suggesting asthma, or restrictive spirometry),
the patient will be referred to the GP.

In practices randomized to the GP-practice nurse partnership management arm, the nurses and GPs will attend further workshops to receive practical training in
team-based management of COPD. These additional
workshops for GPs and practice nurses in the GPpractice nurse partnership intervention will be provided
by the study team including a nurse academic, a GP academic, and a respiratory physician. The intervention
workshops will comprise a full day for practice nurses, a
distance learning activity for GPs, and an evening workshop for both practice nurses and GPs.
The one-day training workshop for nurses will cover:
pathophysiology and assessment of COPD; smoking cessation including use of lung age as a motivational tool
[27]; COPD management according to Australian guidelines [17]; prescribing guidelines; assessment of patients’
inhaler technique and education to improve technique
[43]; the role of pulmonary rehabilitation; the management of exacerbations; the use and value of nurse/GP
joint care planning; information about reimbursement
codes for relevant activities; and education about selfefficacy theory, motivation, change management, teamwork, and fostering partnerships. The program will be
based on that used in an earlier study [44], with adaptation to address specific issues for patients with newlydiagnosed COPD. It will foster a culture of positive
organisational change through team building and promotion of collaborative practice [45]. Practice nurses will
be provided with a folder containing workshop notes
and presentations.
GPs will complete a computer-based distance learning
activity and quiz on the management of COPD according to the COPDX guidelines. The evening three-hour
workshop for GPs and practice nurses will focus on the
importance for each GP-practice nurse team to clarify
individual elements of their roles, because lack of understanding has been shown to be a barrier to collaborative
practice [46,47]. Each practice will be provided with a
copy of current Australian COPD guidelines [17].
Control group training

After case-finding training, practices that are randomized to usual care will be provided with a print copy of

Study procedures
Intervention and Control Groups—case-finding
appointments

Intervention group—delivery of GP-Practice nurse team
management for newly-diagnosed COPD

In the intervention practices, the practice nurse will work
in partnership with the GP and patient to develop a care
plan for patients newly-diagnosed as having COPD. The
workbooks provided during the intervention group training workshops will prompt the nurse and GP to include
relevant components of the following in the care plan:
1. Smoking cessation: advice based on Smoking
Cessation Guidelines for Australian General
Practice [50].
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2. Immunization: influenza and pneumococcal
vaccination status will be assessed relative to local
guidelines [51], and immunization recommended and
provided where appropriate.
3. Exercise: recommendation about regular exercise for
all patients regardless of COPD severity; patients
with moderate or severe COPD provided with details
of their local pulmonary rehabilitation provider.
4. Medication review: review of current medications
and education about potential future indications for
pharmacotherapy. For patients already using any
inhaler, inhaler technique will be checked using
published checklists [43]. Patients for whom inhaled
medication is indicated will be educated on the
appropriate use of these using established
protocols [43].
5. Nutrition: Advice about diet and exercise and referral
to a dietician if appropriate for overweight or
underweight patients.
6. Psychosocial issues: identification and management
of anxiety and/or depression.
7. Co-morbidities and complications of COPD will be
assessed and managed.
8. Patient education: patients will be provided with
written information about COPD (from Australian
Lung Foundation http://www.lungfoundation.com.
au/) and its management and with information about
local patient support groups which provide
emotional support and self-management information.
The nurse and GP will work in partnership with the
patient to implement care plans using appropriate prescribing, investigations, referral, and follow-up consultations with the GP, and visits or telephone consultations
with the practice nurse. Patients will be added to a
COPD Register within the practice to facilitate appropriate recall and reminder notifications and monitor patient
progress. This will allow recording of implementation
milestones in patient care plans, outstanding actions,
and review arrangements. The guideline-based care plan
for each patient will seek to optimise management, improve function, prevent deterioration, and enhance patient knowledge and skills. It may be informal, or may
be documented in line with government-funded reimbursement programs for chronic disease care [32].
Control group: usual care for newly-diagnosed COPD

In the control practices, at the completion of the casefinding visit, the nurse will recommend that patients
with newly-diagnosed COPD should see their GP for
management of the condition. Usual care for the purpose of this study will thus be the normal pattern of care
of COPD by the GP; to ensure that all GPs have access
to current Australian COPD guidelines, they will be
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provided with a print copy [17]. All current smokers will
be offered brief smoking cessation advice at the casefinding visit, regardless of the results of spirometry.
Intervention and control groups: mentoring of
practice nurses

Brief periodic mentoring will be provided to all practice
nurses by experienced registered nurses in order to facilitate compliance with study processes, to enhance recruitment and retention of patients, and to provide a
standardised framework for responding to questions.
Intervention and control practices will receive similar
levels of spirometry mentoring. Intervention practices
alone will receive mentoring relating to GP-nurse case
management of COPD. Mentoring of intervention and
control practices will be carried out by two different
registered nurses to avoid any cross-contamination between randomisation groups.
Outcome measures
Data collection—patients

Once the project officer has received the consent form,
contact details, and spirometry worksheet for a patient,
they will arrange a visit as soon as possible for baseline
assessment, either at the patient’s home or at the GP’s
practice according to patient preference. The project
officer will collect demographic data including age, gender, body mass index, employment status, education,
and country of birth, and data for outcome and process
measures. Further data collection will occur at 6 months
(by telephone and mail) and 12 months (face to face).
Outcome measures—patients

The primary outcome measure will be disease-specific quality of life assessed by the St George’s Respiratory Questionnaire (SGRQ [52]). Secondary outcome measures include:
patient awareness of COPD diagnosis, COPD Assessment
Test (CAT, a disease specific QOL measure [53]); smoking
status by self-report and from carbon monoxide analysis
(Smokerlyzer, Bedfont Scientific Ltd, Maidstone, UK) and
readiness to quit if applicable; immunisation rates; medication including appropriate inhaler prescription and effective inhaler use; referral for pulmonary rehabilitation or
referral for or provision of exercise prescriptions; disease
related knowledge [54]; patient satisfaction; healthcare
utilisation; and lung function. The relationship between
objectives, outcomes, measures, and hypothesis is outlined
in Table 1.
Process measures

At each visit/telephone call, patients will be asked the
number of times they have visited the GP and/or practice nurse (total, and COPD-related), and the COPDrelated areas addressed. At the end of the study, GPs
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Table 1 Relationships between objectives, outcomes, measures and hypotheses
Objective

Hypothesis

To assess the effectiveness
of early intervention by a
GP-practice nurse partnership,
in patients newly identified as
having COPD

Early intervention by a
Improvement in disease related
GP–practice nurse
quality of life
partnership will improve
outcomes for patients
Improved smoking cessation rates
with COPD, compared
with usual care

To assess the acceptability
and feasibility of team-based
vs conventional management
of patients with COPD

Outcome

Measure

Visit

St George’s Respiratory Questionnaire
(SGRQ) [52]

1,2,3

COPD Assessment Test (CAT)

1,2,3

Participation in smoking cessation
program; quit rates (self-report)

1,2,3

Validation of smoking cessation
(where applicable)
by carbon monoxide analysis

1,3

Improved compliance with
COPD immunisation
recommendations

Influenza and pneumococcal
vaccination status (self-reported)

1,3

Improved prescribing and use of
medications for COPD

Audit of prescribing against
COPD-X guidelines

1,2,3

Inhaler technique score using
published checklists [43]

1,3

Increased referral for pulmonary
rehabilitation

Completion of pulmonary rehabilitation 1,2,3
(self-reported)

Increase in disease related
knowledge

COPD knowledge questionnaire
score [54]

1,3

Improved general health status

General health status question (using
preliminary question from SGRQ) [52].

1,2,3

Slower decline in lung function

Post-bronchodilator FEV1

1,3

Improved team-work between GP Collaborative Practice Scale, VAS scale
and practice nurse
for team management of COPD

End of study

Barriers and facilitators to
team-work management
of COPD

Process measures relating to GP
and PN visits.

1, 2, 3

Semi-structured interviews with GPs,
PNs, patients

End of study

and practice nurses in both groups will be asked to rate
the extent to which they practice team-based management of COPD, on a visual analogue scale. Practice
nurses and GPs will complete the Collaborative Practice
Scale [55] to assess the ‘interactions between nurses and
GPS that enable the knowledge and skills of both professionals to synergistically influence patient care’ [55].
Semi-structured interviews at the conclusion of the project with the practice nurses, GPs, and patients will examine satisfaction with the program and will explore the
effects and value of the nurse input into COPD diagnosis
and care, and barriers and facilitators to the teammanagement approach. The software package NVivoW will
be used to facilitate coding and exploration of the data.

(AUD38.50 for each appointment, for up to 60
patients per practice); continuing professional
development points for workshop attendance.
2. Intervention group: reimbursement for practice
nurse attendance at the COPD team management
workshop (AUD270); reimbursement for GP
attendance at the team management workshop
(AUD450); category two continuing professional
development points for GPs.

Reimbursement

Once a diagnosis of COPD is made, any medical or practice nurse consultations that are required for clinical management may be funded through normal practice processes.
Small gifts (food baskets) will be provided to practice
reception staff as thanks for their assistance in making
follow-up telephone calls.

The project will provide the following support to participating practices:

Data analysis

1. Intervention and control practices: Reimbursement
for the practice nurse attendance at the COPD
diagnosis and spirometry workshop (AUD270);
payment for the practice nurse to undertake the
medical record search (AUD500); reimbursement for
practice nurse time for case-finding consultations

Data collation will be managed using Access, and data
analysis undertaken using the Statistical Package for the
Social Sciences (SPSS) by a statistician blind to group allocation. Analysis will be by intention to treat, i.e., by
the diagnosis assigned by the practice nurse/GP on the
basis of case-finding spirometry, including patients
whose diagnosis of COPD is not confirmed by the
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project officer. Intra-cluster (practice) correlation coefficients will be determined and published for all primary
outcome variables to assist future research.
The effect of the intervention on outcomes measured
on a continuous scale (such as SGRQ score) will be estimated and tested using mixed model analysis of variance
in which time and treatment group will be fixed effects
and GP practice and subject nested within practice will
be random effects. The effect of the intervention on the
dichotomous variables (such as smoking and vaccination
status) will be analysed using generalised estimating
equations with a logistic link and a model structure that
is analogous to that described above.
Sample size calculations

The sample size calculation is based on a minimum clinically important difference for the primary outcome
measure (SGRQ) of 4.0 [52], between subject standard
deviation in SGRQ of 13 in a similar population [54],
intra-cluster correlation coefficient of 0.01, and a resultant design effect of 1.09 for a cluster size of 10. With
this design effect, a sample size of 200 patients completing each arm will provide >80% power to detect a difference of 4 or greater in SGRQ (calculations in PASS
software). Forty practices will each invite 300 patients to
attend a case-finding appointment, and within each
practice this is expected to produce 12 patients with a
new diagnosis of COPD; loss to follow-up of 20% by
12 months has been assumed. The projected recruitment
rate is derived from the response rate to invitation
(25%), and the yield of new diagnoses (21%) in our recently completed case-finding project [10].
This sample size will also confer 90% power to identify
a doubling of the expected rate of correct inhaler use
(from 20% to 40%) at a significance level of 5% (based
on an ICCC of 0.1, and design effect of 2.1).

Discussion
There is substantial evidence that COPD is underdiagnosed in the community, and that even once a diagnosis of COPD is made, many patients are not managed
according to evidence-based guidelines. By the time the
diagnosis is made, COPD is often far-advanced, limiting
the benefit that could potentially be achieved through
early intervention with strategies such as smoking cessation, dietary advice, and increased exercise. This study
will use proven case-finding methods in an at-risk population to identify new patients with COPD, followed by a
pragmatic cluster randomised study design to test a
novel intervention designed to improve the implementation of evidence-based guidelines for newly-diagnosed
COPD. Practice nurses and GPs will be trained in practical strategies for assessing and managing COPD, and in
working as a team in managing patients with chronic
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diseases. Elements of the intervention have been piloted
and found to be feasible. The impact of this team-based
approach to COPD management on quality of life will
be compared with usual care using a widely used and
validated tool (SGRQ). Other outcome measures will
evaluate the concordance of patient management with
evidence-based guidelines for management of COPD,
using instruments with demonstrated validity and reliability, which are congruent with the recommendations
of the ERS/ATS Task Force on COPD trials [56]. In
addition, the acceptability of the team management approach to GPs and practice nurses, and barriers and
facilitators to its implementation, will be evaluated with
structured interviews at study end.
This study targets COPD patients in general practice
where the contact with potential patients with mild and
moderate COPD is greatest, and where improved care
has the potential for substantial health benefit. Because
COPD is a major contributor to the burden of disease in
countries such as Australia, improved care is of great
public health significance. If successful, the trial will provide a model for care of COPD patients in the community that is feasible and sustainable. Publication of the
results of the trial will influence policy and practice on
how care for COPD is provided at a national and international level.
Sustainability of the intervention

In this pragmatic study, the intervention deliberately
makes use of and augments existing practice structures,
staffing, and approaches to chronic disease management.
While there is potential for nurses to undertake
advanced practice in primary care, this study will not require practice nurses to work at an advanced practice
level. For this study, the role of the practice nurse is focussed on patient assessment; counselling; education;
and liaison with medical and allied health colleagues,
using expertise that forms part of the skills base of registered nurses. The intervention is thus potentially
generalizable and easily transferable.
Abbreviations
BOLD: Burden of Obstructive Lung Disease; CAT: COPD Assessment Test;
CDQ: COPD diagnostic questionnaire; COPD: Chronic obstructive pulmonary
disease; FEV1: Forced expiratory volume in one second; GOLD: Global
Initiative for Chronic Obstructive Pulmonary Disease; GP: General practitioner;
PELICAN: Primary care EarLy Intervention for Copd mANagement;
PN: Practice nurse; SGRQ: St George’s Respiratory Questionnaire.
Competing interests
HR has participated on COPD advisory committees for Novartis, has spoken
about COPD guidelines at symposia funded by AstraZeneca and Boehringer
Ingelheim, has received travel support from AstraZeneca, GlaxoSmithKline
and Novartis, and has received independent research funding from
GlaxoSmithKline for an investigator-initiated COPD study. GBM is on an
advisory board for Novartis and his institution has received funds from
AstraZeneca for consultancies. He has spoken at education symposia
sponsored by AstraZeneca and GlaxoSmithKline. NZ has provided expert

Bunker et al. Implementation Science 2012, 7:83
http://www.implementationscience.com/content/7/1/83

advice on smoking cessation education programs to Pfizer Pty Ltd and
GlaxoSmithKline Australia Pty Ltd and has received support to attend
smoking cessation conferences. Other authors have no competing interests.
Authors’ contributions
The study was conceived by JB, NZ and GM, and all authors contributed to
the study design. CPvS advised on the design of the CDQ utility study. AC
designed the spirometry toolkit for diagnosis of COPD. HR wrote the initial
draft of the manuscript. All authors contributed to and approved the final
version of the manuscript.
Acknowledgements
This paper honours the memory of Jeremy Bunker, without whose initiative
and enthusiasm this study would not have taken place. The study was
funded by the National Health and Medical Research Council, Project Grant
No. 630421. The input of Professor S Teng Liaw into the study design, and
Charmaine Rodricks for administrative assistance, are appreciated.
Author details
1
School of Public Health and Community Medicine, University of New South
Wales, Sydney, NSW 2052, Australia. 2Woolcock Institute of Medical Institute,
University of Sydney, Sydney, NSW, Australia. 3Centre for Primary Health Care
and Equity, University of New South Wales, Sydney, NSW 2052, Australia.
4
National Centre for Clinical Outcomes Research, Australia, Australian Catholic
University, Sydney, NSW, Australia. 5Research School Caphri, Maastricht
University, Maastricht, The Netherlands. 6Discipline of General Practice,
School of Population Health And Clinical Practice, The University of Adelaide,
Adelaide 5005, South Australia. 7General Practice Unit, Fairfield Hospital,
South Western Sydney Local Health District/School of Public Health &
Community Medicine, University of New South Wales, Sydney, NSW 2052,
Australia. 8Woolcock Institute of Medical Research, University of Sydney and
Department of Respiratory Medicine, Liverpool Hospital, Liverpool, NSW
2170, Australia.
Received: 29 June 2012 Accepted: 29 August 2012
Published: 7 September 2012
References
1. World Health Organization: Global surveillance, prevention and control of
chronic respiratory diseases: a comprehensive approach. In Book Global
surveillance, prevention and control of chronic respiratory diseases: a
comprehensive approach. City: World Health Organization; 2007.
2. Mathers CD, Loncar D: Projections of Global Mortality and Burden of
Disease from 2002 to 2030. PLoS Med 2006, 3:e442.
3. Australian Institute of Health and Welfare: Australia's Health 2010.
Canberra: AIHW; 2010.
4. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM,
Menezes AMB, Sullivan SD, Lee TA, Weiss KB, et al: International variation in
the prevalence of COPD (the BOLD Study): a population-based
prevalence study. Lancet 2007, 370:741–750.
5. Toelle B, Xuan W, Bird T, Abramson M, Burton DH M, Johns D, Maguire G,
Wood-Baker R, Marks G: COPD in the Australian Burden Of Lung Disease
(BOLD) study. Respirology 2011, 16:12.
6. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD): Global
Strategy for Diagnosis, Management and Prevention of COPD. 2011.
www.goldcopd.com. Date accessed: November 201.
7. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E,
Larsson LG, Andersson S, Sandstrom T, Larsson K: Obstructive Lung Disease
in Northern Sweden S: Not 15 but 50% of smokers develop
COPD?–Report from the Obstructive Lung Disease in Northern
Sweden Studies. Respir Med 2003, 97:115–122.
8. Roche N, Dalmay F, Perez T, Kuntz C, Vergnenegre A, Neukirch F,
Giordanella JP, Huchon G: Impact of chronic airflow obstruction in a
working population. Eur Respir J 2008, 31:1227–1233.
9. Akazawa M, Halpern R, Riedel AA, Stanford RH, Dalal A, Blanchette CM:
Economic burden prior to COPD diagnosis: a matched case-control
study in the United States. Respir Med 2008, 102:1744–1752.
10. Bunker J, Hermiz O, Zwar N, Dennis SM, Vagholkar S, Crockett A, Marks G:
Feasibility and efficacy of COPD case finding by practice nurses. Aust
Fam Physician 2009, 38:826–830.

Page 9 of 10

11. Buffels J, Degryse J, Heyrman J, Decramer M, Study D: Office spirometry
significantly improves early detection of COPD in general practice: the
DIDASCO Study. Chest 2004, 125:1394–1399.
12. Stratelis G, Jakobsson P, Molstad S, Zetterstrom O: Early detection of COPD
in primary care: screening by invitation of smokers aged 40 to 55 years.
Br J Gen Pract 2004, 54:201–206.
13. Van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ:
Detecting patients at a high risk of developing chronic obstructive
pulmonary disease in general practice: cross sectional case finding
study. BMJ 2002, 324:1370.
14. Levy ML, Quanjer PH, Booker R, Cooper BG, Holmes S, Small I, General
Practice Airways Group: Diagnostic spirometry in primary care: Proposed
standards for general practice compliant with American Thoracic Society
and European Respiratory Society recommendations: a General Practice
Airways Group (GPIAG) document, in association with the Association
for Respiratory Technology & Physiology (ARTP) and Education for
Health. Prim Care Respir J 2009, 18:130–147.
15. DeJong SR, Veltman RH: The effectiveness of a CNS-led community-based
COPD screening and intervention program. Clin Nurse Spec 2004,
18:72–79.
16. Bolton CE, Ionescu AA, Edwards PH, Faulkner TA, Edwards SM, Shale DJ:
Attaining a correct diagnosis of COPD in general practice. Respir Med
2005, 99:493–500.
17. McKenzie DK, Abramson M, Crockett AJ, Glasgow N, Jenkins S, McDonald C,
Wood-Baker R, Frith PA, on behalf of The Australian Lung Foundation: The
COPD-X Plan: Australian and New Zealand Guidelines for the management of
Chronic Obstructive Pulmonary Disease 2011. Lutwyche, Queensland: Australian
Lung Foundation. 2011. www.copdx.org.au. Date accessed: February 2012.
18. Ta M, George J: Management of chronic obstructive pulmonary disease
in Australia after the publication of national guidelines. Intern Med J 2011,
41:263–270.
19. Matheson MC, Abeysena C, Raven JM, Skoric B, Johns DP, Abramson MJ,
Walters EH: How have we been managing chronic obstructive pulmonary
disease in Australia? Intern Med J 2006, 36:92–99.
20. Mularski RA, Asch SM, Shrank WH, Kerr EA, Setodji CM, Adams JL, Keesey J,
McGlynn EA: The quality of obstructive lung disease care for adults in
the United States as measured by adherence to recommended
processes. Chest 2006, 130:1844–1850.
21. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M,
Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, et al: Effect of incorrect use of
dry powder inhalers on management of patients with asthma and
COPD. Respir Med 2008, 102:593–604.
22. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M,
Scichilone N, Sestini P, Aliani M, et al: Inhaler mishandling remains
common in real life and is associated with reduced disease control.
Respir Med 2011, 105:930–938.
23. Doherty DE: Early detection and management of COPD. What you can
do to reduce the impact of this disabling disease. Postgrad Med 2002,
111:41–44. 49-50, 53 passim.
24. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS,
Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al: Effects of smoking
intervention and the use of an inhaled anticholinergic bronchodilator on
the rate of decline of FEV1. The Lung Health Study. JAMA 1994,
272:1497–1505.
25. Kanner RE, Connett JE, Williams DE, Buist AS: Effects of randomized
assignment to a smoking cessation intervention and changes in
smoking habits on respiratory symptoms in smokers with early chronic
obstructive pulmonary disease: the Lung Health Study. Am J Med 1999,
106:410–416.
26. Smith-Sivertsen T, Rortveit G: Should general practitioners screen smokers
for COPD? Scand J Prim Health Care 2004, 22:196–201.
27. Parkes G, Greenhalgh T, Griffin M, Dent R: Effect on smoking quit rate of
telling patients their lung age: the Step2quit randomised controlled trial.
BMJ 2008, 336:598–600.
28. Levy ML, Fletcher M, Price DB, Hausen T, Halbert RJ, Yawn BP: International
Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of
respiratory diseases in primary care. Prim Care Respir J 2006,
15:20–34.
29. Meulepas MA, Jacobs JE, Lucas AEM, Smeenk FWJM, Smeele I, Bottema
BJAM, Grol RPTM: The feasibility of a primary care model for the
management of COPD. Prim Care Respir J 2006, 15:337–341.

Bunker et al. Implementation Science 2012, 7:83
http://www.implementationscience.com/content/7/1/83

30. Harris M, Blakeman T: Enhanced primary care items. Their use in diabetes
management. Aust Fam Physician 2001, 30:1134–1140.
31. Clark N, Lachance L, Milanovich AF, Stoll S, Awad DF: Characteristics of
successful asthma programs. Public Health Rep 2009, 124:797–805.
32. Blakeman TM, Harris MF, Comino EJ, Zwar NA: Evaluating general
practitioners' views about the implementation of the Enhanced Primary
Care Medicare items. Med J Aust 2001, 175:95–98.
33. Zwar NA, Comino EJ, Hasan I, Harris MF, Primary Health Care Research N:
General practitioner views on barriers and facilitators to implementation
of the Asthma 3+ Visit Plan. Med J Aust 2005, 183:64–67.
34. Vrijhoef HJ, Diederiks JP, Spreeuwenberg C: Effects on quality of care for
patients with NIDDM or COPD when the specialised nurse has a central
role: a literature review. Patient Educ Couns 2000, 41:243–250.
35. Wong CX, Carson KV, Smith BJ: Home care by outreach nursing for
chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2011, CD000994.
36. Zakrisson A-B, Engfeldt P, Hagglund D, Odencrants S, Hasselgren M, Arne M,
Theander K: Nurse-led multidisciplinary programme for patients with
COPD in primary health care: a controlled trial. Prim Care Respir J 2011,
20:427–433.
37. Canesi M, Montrasio A, Di Mauro S: The contribution of nurses in
integrated primary cares for chronic obstructive pulmonary disease
outpatient: first results from an ongoing trial in a health district in
northern Italy. Journal of Medicine and the Person 2012, 10:30–33.
38. Campbell MK, Elbourne DR, Altman DG: CONSORT statement: extension to
cluster randomised trials. BMJ 2004, 328:702–708.
39. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B,
Oxman AD, Moher D, group C, Pragmatic Trials in Healthcare g: Improving
the reporting of pragmatic trials: an extension of the CONSORT
statement. BMJ 2008, 337:a2390.
40. Australian Bureau of Statistics: Socio-Economic Indices for Areas (technical
paper). Canberra: Australian Bureau of Statistics; 2006.
http://www.abs.gov.au/ausstats/abs@.nsf/mf/2039.0.55.001/.
Date accessed: January 2009.
41. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A,
Enright P, van der Grinten CPM, Gustafsson P, et al: General considerations
for lung function testing. Eur Respir J 2005, 26:153–161.
42. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A,
van der Grinten CPM, Gustafsson P, Hankinson J, et al: Interpretative
strategies for lung function tests. Eur Respir J 2005, 26:948–968.
43. Inhaler technique in adults with asthma or COPD.
http://www.nationalasthma.org.au/html/management/info_inhaler/
Inhaler_technique_in_adults_with_asthma_or_COPD.pdf.
44. Zwar N, Hermiz O, Hasan I, Comino E, Middleton S, Vagholkar S, Marks G: A
cluster randomised controlled trial of nurse and GP partnership for care
of chronic obstructive pulmonary disease. BMC Pulm Med 2008, 8:8.
45. Patterson E, McMurray A: Collaborative practice between registered
nurses and medical practitioners in Australian General Practice: Moving
from rhetoric to reality. Aust J Adv Nurs 2003, 20:43–48.
46. Stichler JF: Professional interdependence: the art of collaboration.
Advanced Nursing Practice Quarterly 1995, 1:53–61.
47. Chan BC, Perkins D, Wan Q, Zwar N, Daniel C, Crookes P, Harris MF,
Team-link project t: Finding common ground? Evaluating an intervention
to improve teamwork among primary health-care professionals. Int J
Qual Health Care 2010, 22:519–524.
48. Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D,
Juniper EF, Freeman D, Hausen T, Levy ML, et al: Symptom-based
questionnaire for identifying COPD in smokers. Respiration 2006,
73:285–295.
49. Primary Care Respiratory Toolkit. http://www.lungfoundation.com.au/
professional-resources/general-practice/primary-care-respiratory-toolkit.
50. Zwar N, Richmond R, Borland R, Stillman S, Cunningham M, Litt J: Smoking
cessation guidelines for Australian general practice. In Book Smoking
cessation guidelines for Australian general practice. City: Commonwealth of
Australia; 2004.
51. National Immunisation Handbook. http://immunise.health.gov.au/internet/
immunise/publishing.nsf/Content/Handbook-home.
52. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure
of health status for chronic airflow limitation. The St. George's
Respiratory Questionnaire. Am Rev Respir Dis 1992,
145:1321–1327.

Page 10 of 10

53. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N:
Development and first validation of the COPD Assessment Test.
Eur Respir J 2009, 34:648–654.
54. Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M: Randomised
controlled trial of home based care of patients with chronic obstructive
pulmonary disease. BMJ 2002, 325:938.
55. Weiss SJ, Davis HP: Validity and reliability of the Collaborative Practice
Scales. Nurs Res 1985, 34:299–305.
56. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ,
Brusasco V, Burge PS, Calverley PMA, Celli BR, et al: Outcomes for COPD
pharmacological trials: from lung function to biomarkers. Eur Respir J
2008, 31:416–469.
doi:10.1186/1748-5908-7-83
Cite this article as: Bunker et al.: A pragmatic cluster randomized
controlled trial of early intervention for chronic obstructive pulmonary
disease by practice nurse-general practitioner teams: Study Protocol.
Implementation Science 2012 7:83.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

BioMed Central publishes under the Creative Commons Attribution License (CCAL). Under the CCAL, authors
retain copyright to the article but users are allowed to download, reprint, distribute and /or copy articles in
BioMed Central journals, as long as the original work is properly cited.

